2. Signaling Pathways
  3. Antibody-drug Conjugate/ADC Related
  4. Radionuclide-Drug Conjugates (RDCs)

Radionuclide-Drug Conjugates (RDCs)

ADC-Related Custom Services

Radionuclide-drug conjugates (RDCs) are one of the most promising development directions for nuclear drug targeted therapy. RDC is composed of targeting element, linker, chelate and radioactive isotope. RDC has advantages in early tumor diagnosis, treatment and postoperative tumor evaluation. The same ligand can be connected to nuclides used for disease diagnosis and treatment respectively, promoting the integration of diagnosis and treatment of RDC drugs.

Radionuclide-Drug Conjugates (RDCs) Isoform Specific Products:

Radionuclide-Drug Conjugates (RDCs) Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P9907
    Trastuzumab
    		99.80%
    Trastuzumab is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.
    Trastuzumab
  • HY-P9905
    Cetuximab
    		99.70%
    Cetuximab (C225) is a human IgG1 monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a Kd of 0.201 nM for EGFR by SPR. Cetuximab has potent antitumor activity.
    Cetuximab
  • HY-P9913
    Rituximab
    		99.85%
    Rituximab is an anti-CD20 chimeric monoclonal antibody used for research of certain autoimmune diseases and cancer.
    Rituximab
  • HY-P99239
    Rosopatamab
    		99.47%
    Rosopatamab (HuJ591) is a humanized antiPSMA IgG1 monoclonal antibody that can be used in cancer research, especially prostate cancer. Rosopatamab can be linked to the low-energy beta-emitting radioisotope lutetium-177 (177Lu) through the bifunctional chelator DOTA-NHS ester to obtain a radioimmunoconjugate that targets malignant prostate cells with high efficiency.
    Rosopatamab
  • HY-125399
    PSMA-11
    		99.74%
    PSMA-11 is a small molecule ligand that targets prostate-specific membrane antigen (PSMA) and has the ability to inhibit PSMA activity. PSMA-11 can be used to synthesize 68Ga-PSMA-11, a positron emission tomography (PET) tracer that can be used to image advanced prostate cancer.
    PSMA-11
  • HY-W087028
    NOTA-NHS ester
    NOTA-NHS ester is a molecule related to radiolabeling drugs (RDC) that can be used for fluorescent labeling and radioactive nuclide labeling applications.
    NOTA-NHS ester
  • HY-W046355
    Fmoc-D-Dap(Boc)-OH
    		99.56%
    Fmoc-D-Dap(Boc)-OH is an amino acid derivative with an Fmoc protecting group, which can be used to synthesize bioactive peptide mimetics, such as DOTA-modified peptides and their metal chelates with cancer diagnostic effects.
    Fmoc-D-Dap(Boc)-OH
  • HY-W087187
    DOTAGA-anhydride
    DOTAGA-anhydride is a DOTA-based metal chelator that can bind to radionuclides and is used to prepare radionuclide drug conjugates (RDCs). DOTAGA-anhydride can be used to label monoclonal antibodies (mAbs) such as trastuzumab (targeting HER2/neu receptor with an affinity of 5.5 nM) under mild conditions (PBS pH 7.4, 25 °C, 30 minutes) after chelation with indium-111. [111In-DOTAGA]-trastuzumab showed a tumor uptake of 65% ID/g in mice bearing breast cancer BT-474 xenografts 72 hours after injection, which is valuable for SPECT/CT imaging and biodistribution studies.
    DOTAGA-anhydride
  • HY-106244A
    DOTATATE acetate
    		99.82%
    DOTATATE acetate is a DOTA-conjugated peptide. DOTATATE acetate can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT).
    DOTATATE acetate
  • HY-W034551
    DOTA-tri(t-butyl ester)
    		99.46%
    DOTA-tri(t-butyl ester) can be used in the synthesis of generations 3 (G3) nanoglobular magnetic resonance imaging (MRI) contrast agents for MR angiography and tumor angiogenesis imaging.
    DOTA-tri(t-butyl ester)
  • HY-106244
    DOTATATE
    		99.87%
    DOTATATE is a DOTA-conjugated peptide. DOTATATE can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT).
    DOTATATE
  • HY-P3440
    WL12
    		99.99%
    WL12 is a specifically targeting programmed death ligand 1 (PD-L1) binding peptide. WL12 can be radiolabeled by different radionuclides, generating radiotracers, which can assess the tumor PD-L1 expression.
    WL12
  • HY-134797
    p-SCN-Bn-deferoxamine
    		≥98.0%
    p-SCN-Bn-deferoxamine is a linker used to connect antibodies to materials.
    p-SCN-Bn-deferoxamine
  • HY-106033
    Edotreotide
    		98.15%
    Edotreotide is a somatostatin analogue. Edotreotide bound to various radionuclides, has the potential for the research and diagnosis of certain types of cancer.
    Edotreotide
  • HY-W087027
    Maleimide-NOTA
    		99.69%
    Maleimide-NOTA is a chelator for the labeling of peptides and antibodies. Maleimide-NOTA can react with cysteine.
    Maleimide-NOTA
  • HY-P5126
    DOTA-LM3
    		98.22%
    DOTA-LM3 is a somatostatin receptor (SSTR) antagonist. LM3 refers to p-Cl-Phe- cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr- NH2, as well as a somatostatin antagonist. DOTA-LM3 is often isotopically labeled for tracing tumors in vivo, such as 177Lu-DOTA-LM3 and 68 Ga-DOTA-LM3. 68 Ga-DOTA-LM3 shows favorable biodistribution, high tumor uptake, good tumor retention, and few safety concerns. 177Lu-DOTA-LM3 can be used for research in DOTATOC-negative liver metastases, such as pancreatic NET and extensive tumor thrombosis.
    DOTA-LM3
  • HY-P5128
    DOTA-JR11
    		98.81%
    DOTA-JR11 is a somatostatin receptor 2 （SSTR2）antagonist. DOTA-JR11 can be labeled by 68Ga, used for paired imaging in neuroendocrine tumors (NETs) research.
    DOTA-JR11
  • HY-P5126A
    DOTA-LM3 TFA
    		99.30%
    DOTA-LM3 TFA is a somatostatin receptor (SSTR) antagonist. LM3 refers to p-Cl-Phe- cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr- NH2, as well as a somatostatin antagonist. DOTA-LM3 TFA is often isotopically labeled for tracing tumors in vivo, such as 177Lu-DOTA-LM3 TFA and 68 Ga-DOTA-LM3 TFA. 68 Ga-DOTA-LM3 TFA shows favorable biodistribution, high tumor uptake, good tumor retention, and few safety concerns. 177Lu-DOTA-LM3 TFA can be used for research in DOTATOC-negative liver metastases, such as pancreatic NET and extensive tumor thrombosis.
    DOTA-LM3 TFA
  • HY-P10131
    3BP-3940
    		99.96%
    3BP-3940 is a highly potent fibroblast activation protein (FAP)-targeting peptide for theranostics. 3BP-3940 is often coupled with radionuclides for tumor diagnosis and treatment.
    3BP-3940
  • HY-W250574
    NOTA-bis(tBu)ester
    NOTA-bis(tBu)ester (NOTA-bis(t-Butyl ester)), a NOTA derivative, is a bifunctional chelator that can be used for drug coupling.
    NOTA-bis(tBu)ester
Radionuclide-Drug Conjugates (RDCs) Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.